Biolysis Weekly

biolysis weekly is a weekly substack newsletter, intended to provide the investor community with in-depth buy side and sell side analyses of today's publicly traded biopharmaceutical/biotechnology companies. biolysis weekly aspires to demystify the biopharmaceutical/biotechnology industry, and the age-old belief held by many investors that the industry is too niche, volatile, and obscurely complex for sound investment. an additional focus of this newsletter is to bridge the gap in information, simplify the science, and closely follow clinical trials of companies, in order to provide updates, as well as commentary on fda regulatory milestones. these milestones include eua, fast-track, nda, ind, bla applications and much more. ostensibly, in my personal experience, many of these regulatory decisions can act as catalyst and/or dilutive events for companies. so, it will be vital to pay close attention! finally, biolysis weekly aims to shed light on the dark side of the industry; in exp